β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-4-deoxy-D-mannitol | 1034634-96-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-4-deoxy-D-mannitol
• 英文别名: KD397；(2R,3S,5S)-3-[(2R,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-4-[(2S,3R,4S,5R,6R)-3,5-dihydroxy-6-(hydroxymethyl)-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexane-1,2,5,6-tetrol
• CAS: 1034634-96-2
• 化学式: C₃₆H₆₄O₃₀
• 分子量: 976.886
• InChiKey: FHWWBJCDXACVCV-YMDOVSQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -10.6
• 重原子数：
  66
• 可旋转键数：
  20
• 环数：
  5.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  497
• 氢给体数：
  20
• 氢受体数：
  30

反应信息

• 作为产物：
  描述：

  β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-4-deoxy-(α,β)-D-mannopyranose 在 sodium tetrahydroborate 、 水 作用下， 以 甲醇 为溶剂， 反应 168.0h， 以100%的产率得到β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-β-D-glucopyranosyl-(1→3)-4-deoxy-D-mannitol
  参考文献：
  名称：

  New 4-deoxy-(1→3)-β-d-glucan-based oligosaccharides and their immunostimulating potential

  摘要：

  (1→3)-β-D-葡聚糖是公认的天然生物免疫调节剂。然而，这些多糖源于天然所带来的遗传问题，带来了重大挫折，包括批间异质性和基于来源及分离技术的显著差异。在这项研究中，我们试图通过制备一系列定量新的寡-（1→3)-β-D-葡聚糖基合成免疫调节剂来克服这些问题。其中一些非天然寡糖显示出生物活性，如刺激吞噬作用、调控基因表达和抗癌活性，这些活性优于天然葡聚糖。 © 2011 Elsevier Ltd. 保留所有权利。

  DOI：

  10.1016/j.carres.2011.06.020

文献信息

• Use of modified oligo-β-(1,3)-glucans for treating diseases of the immune system, oligo-β-(1,3)-glucan-(1,3)-mannose, oligo-β-(1,3)-glucan-(1,3)-mannitol and derivatives thereof, methods for preparing them and medicaments containing them
  申请人：Yvin Jean-Claude

  公开号：US08367641B2

  公开（公告）日：2013-02-05

  The present invention relates to the use of at least one compound of formula (I) or (II), in which R1 is H and n is an integer from 2 to 10, for the preparation of a medicament for treating diseases chosen from the group comprising tumour, cancer, viral disease, bacterial disease, fungal disease, disease of the immune system, auto-immune disease or disease linked to a deficiency in immunostimulation, in human beings and warm-blooded animals. The invention also relates to new products having a mannose or mannitol termination as well as a method for preparing them.

  本发明涉及使用式(I)或(II)中至少一种化合物，其中R1为H，n为2至10的整数，用于制备用于治疗人类和温血动物中所选疾病的药物，所述疾病包括肿瘤、癌症、病毒性疾病、细菌性疾病、真菌性疾病、免疫系统疾病、自身免疫疾病或与免疫刺激缺乏有关的疾病。该发明还涉及具有甘露糖或甘露醇末端的新产品以及其制备方法。